Immunosuppression: today, tomorrow, and withdrawal

Area of Science:

• Immunology
• Transplantation Medicine
• Pharmacology

Background:

• Liver transplantation has evolved into a primary treatment for end-stage liver disease, largely due to advancements in immunosuppressive therapies.
• Current immunosuppressants, while effective in preventing rejection, lack specificity and are associated with significant toxicities.
• Achieving consistent transplantation tolerance, a key goal, remains elusive, necessitating long-term immunosuppression for recipients.

Purpose of the Study:

• To review current immunosuppressive medications used in liver transplantation.
• To discuss the challenges associated with existing immunosuppressive strategies, including toxicity and lack of specificity.
• To highlight emerging novel immunosuppressive agents and future developments in the field.

Main Methods:

• Review of current literature on immunosuppressive agents in liver transplantation.
• Analysis of the efficacy and toxicity profiles of existing and novel immunosuppressants.
• Discussion of the current state and future directions of immunosuppression research in liver transplantation.

Main Results:

• Modern immunosuppressants have significantly improved short- and long-term outcomes in liver transplantation.
• Despite advancements, current agents require lifelong administration and are linked to acute and chronic toxicities.
• Novel immunosuppressive agents are under investigation, showing promise for future clinical application.

Conclusions:

• Immunosuppression remains critical for successful liver transplantation, but current regimens have limitations.
• The development of more specific and less toxic immunosuppressive agents is a priority.
• Future research aims to achieve transplantation tolerance and reduce the burden of lifelong immunosuppression.